NASDAQ · Healthcare · Biotechnology
Inhibrx Biosciences Inc.
INBX
Inhibrx Biosciences, Inc. CEO Mark Lappe · Market cap $1.4B.
$93.36
-0.05 · -0.05%
52w hi $155.2952w lo $28.16
Off 52w high 34.5%
80
STRONG
Current InsiderScore
Corp · 90d
14
14 buys · 0 sales
Cong · 90d
0
0 buys · 0 sales
Signals ≥ 60 · 12mo
8
3 strong · 5 notable
Analyst consensus
Hold
Avg PT $285.00
Section 01
Recent Form 4 filings
15 filings on file
| Date | Insider | Role | Action | Shares | Price | Value | Score |
|---|---|---|---|---|---|---|---|
| Sep 28 | Mark Lappe | Chief Executive Officer | Buy | 3,000 | $101.70 | +$305K | 59 |
| Sep 28 | Mark Lappe | Chief Executive Officer | Buy | 1,500 | $98.88 | +$148K | 59 |
| Sep 25 | Mark Lappe | Chief Executive Officer | Buy | 3,324 | $98.87 | +$329K | 59 |
| Sep 25 | Mark Lappe | Chief Executive Officer | Buy | 2,176 | $99.60 | +$217K | 59 |
| Sep 23 | Jon Faiz Kayyem | Buy | 5,000 | $100.00 | +$500K | 36 | |
| Sep 16 | Jon Faiz Kayyem | Buy | 5,000 | $100.00 | +$500K | 36 | |
| Sep 08 | Mark Lappe | Chief Executive Officer | Buy | 1,219 | $111.88 | +$136K | 74 |
| Sep 08 | Douglas Forsyth | Buy | 2,500 | $114.65 | +$287K | 65 | |
| Sep 08 | Mark Lappe | Chief Executive Officer | Buy | 1,100 | $107.12 | +$118K | 74 |
| Sep 08 | Mark Lappe | Chief Executive Officer | Buy | 6,605 | $100.64 | +$665K | 77 |
| Sep 08 | Jon Faiz Kayyem | Buy | 5,000 | $113.52 | +$568K | 68 | |
| Sep 08 | Mark Lappe | Chief Executive Officer | Buy | 5,895 | $99.29 | +$585K | 77 |
| Sep 08 | Mark Lappe | Chief Executive Officer | Buy | 9,681 | $112.28 | +$1.09M | 80 |
| Sep 08 | Mark Lappe | Chief Executive Officer | Buy | 500 | $108.23 | +$54K | 71 |
| Oct 07 | VIKING GLOBAL INVESTORS LP | Sell | 308,643 | $32.25 | −$9.95M | 35 |
Section 02
Recent STOCK Act disclosures
No disclosures yet
No STOCK Act disclosures on record for this ticker.
Section 03
InsiderScore history
Rolling 12 months · peak score per month
NovDecJanFebMarAprMayJunJulAugSepOct